Label: TIMOPTIC- timolol maleate solution

  • NDC Code(s): 25010-812-56, 25010-813-16, 25010-813-56
  • Packager: Aton Pharma, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated 09/13

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    STERILE OPHTHALMIC SOLUTION

    Close
  • DESCRIPTION

    TIMOPTIC1 (timolol maleate ophthalmic solution) is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3- [(4-morpholino-1, 2, 5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:

    25°
    [α] in 1.0N HCl (C = 5%) = –12.2° (–11.7° to –12.5°).
    405 nm

    Its molecular formula is C13H24N4O3S•C4H4O4 and its structural formula is:

    Timolol Maleate Chemical Structure

    Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. TIMOPTIC is stable at room temperature.

    TIMOPTIC Ophthalmic Solution is supplied as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths: Each mL of TIMOPTIC 0.25% contains 2.5 mg of timolol (3.4 mg of timolol maleate). The pH of the solution is approximately 7.0, and the osmolarity is 274-328 mOsm. Each mL of TIMOPTIC 0.5% contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients: monobasic and dibasic sodium phosphate, sodium hydroxide to adjust pH, and water for injection. Benzalkonium chloride 0.01% is added as preservative.


    1
    Registered trademark of ATON PHARMA, INC.
    COPYRIGHT © 2013 ATON PHARMA, INC.
    All rights reserved
    Close
  • CLINICAL PHARMACOLOGY

    Mechanism of Action

    Timolol maleate is a beta1 and beta2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

    Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

    Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

    TIMOPTIC Ophthalmic Solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

    The onset of reduction in intraocular pressure following administration of TIMOPTIC can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of TIMOPTIC is well maintained.

    The precise mechanism of the ocular hypotensive action of TIMOPTIC is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.

    Pharmacokinetics

    In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of TIMOPTIC 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.

    Clinical Studies

    In controlled multiclinic studies in patients with untreated intraocular pressures of 22 mmHg or greater, TIMOPTIC 0.25 percent or 0.5 percent administered twice a day produced a greater reduction in intraocular pressure than 1, 2, 3, or 4 percent pilocarpine solution administered four times a day or 0.5, 1, or 2 percent epinephrine hydrochloride solution administered twice a day.

    In these studies, TIMOPTIC was generally well tolerated and produced fewer and less severe side effects than either pilocarpine or epinephrine. A slight reduction of resting heart rate in some patients receiving TIMOPTIC (mean reduction 2.9 beats/minute standard deviation 10.2) was observed.

    Close
  • INDICATIONS AND USAGE

    TIMOPTIC Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

    Close
  • CONTRAINDICATIONS

    TIMOPTIC is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see WARNINGS); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see WARNINGS); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

    Close
  • WARNINGS

    As with many topically applied ophthalmic drugs, this drug is absorbed systemically.

    The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate (see CONTRAINDICATIONS).

    Cardiac Failure

    Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition of beta-adrenergic receptor blockade may precipitate more severe failure.

    In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, TIMOPTIC should be discontinued.

    Obstructive Pulmonary Disease

    Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which TIMOPTIC is contraindicated [see CONTRAINDICATIONS]) should, in general, not receive beta-blockers, including TIMOPTIC.

    Major Surgery

    The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.

    If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.

    Diabetes Mellitus

    Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

    Thyrotoxicosis

    Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.

    Close
  • PRECAUTIONS

    General

    Because of potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with TIMOPTIC, alternative therapy should be considered.

    There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. (See PRECAUTIONS, Information for Patients.)

    Choroidal detachment after filtration procedures has been reported with the administration of aqueous suppressant therapy (e.g. timolol).

    Angle-closure glaucoma

    In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil. Timolol maleate has little or no effect on the pupil. TIMOPTIC should not be used alone in the treatment of angle-closure glaucoma.

    Anaphylaxis

    While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

    Muscle Weakness

    Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.

    Information for Patients

    Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

    Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. (See PRECAUTIONS, General.)

    Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.

    Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. (See CONTRAINDICATIONS.)

    Patients should be advised that TIMOPTIC contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following TIMOPTIC administration.

    Drug Interactions

    Although TIMOPTIC used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with TIMOPTIC and epinephrine has been reported occasionally.

    Beta-adrenergic blocking agents

    Patients who are receiving a beta-adrenergic blocking agent orally and TIMOPTIC should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.

    Calcium antagonists

    Caution should be used in the coadministration of beta-adrenergic blocking agents, such as TIMOPTIC, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, coadministration should be avoided.

    Catecholamine-depleting drugs

    Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

    Digitalis and calcium antagonists

    The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.

    CYP2D6 inhibitors

    Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, SSRIs) and timolol.

    Clonidine

    Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. There have been no reports of exacerbation of rebound hypertension with ophthalmic timolol maleate.

    Injectable epinephrine

    (See PRECAUTIONS, General, Anaphylaxis)

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    In a two-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.

    In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine polyps and mammary adenocarcinomas in female mice at 500 mg/kg/day, (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.

    The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.

    Timolol maleate was devoid of mutagenic potential when tested in vivo (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and in vitro in a neoplastic cell transformation assay (up to 100 mcg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 mcg/plate, were associated with statistically significant elevations of revertants observed with tester strain TA100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.

    Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose.

    Pregnancy

    Teratogenic Effects

    Pregnancy Category C

    Teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.

    There are no adequate and well-controlled studies in pregnant women. TIMOPTIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Nursing Mothers

    Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from TIMOPTIC in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    Geriatric Use

    No overall differences in safety or effectiveness have been observed between elderly and younger patients.

    Close
  • ADVERSE REACTIONS

    The most frequently reported adverse experiences have been burning and stinging upon instillation (approximately one in eight patients).

    The following additional adverse experiences have been reported less frequently with ocular administration of this or other timolol maleate formulations:

    BODY AS A WHOLE

    Headache, asthenia/fatigue, and chest pain.

    CARDIOVASCULAR

    Bradycardia, arrhythmia, hypotension, hypertension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, edema, claudication, Raynaud's phenomenon, and cold hands and feet.

    DIGESTIVE

    Nausea, diarrhea, dyspepsia, anorexia, and dry mouth.

    IMMUNOLOGIC

    Systemic lupus erythematosus.

    NERVOUS SYSTEM/PSYCHIATRIC

    Dizziness, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including depression, confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss.

    SKIN

    Alopecia and psoriasiform rash or exacerbation of psoriasis.

    HYPERSENSITIVITY

    Signs and symptoms of systemic allergic reactions, including anaphylaxis, angioedema, urticaria, and localized and generalized rash.

    RESPIRATORY

    Bronchospasm (predominantly in patients with preexisting bronchospastic disease), respiratory failure, dyspnea, nasal congestion, cough and upper respiratory infections.

    ENDOCRINE

    Masked symptoms of hypoglycemia in diabetic patients (see WARNINGS).

    SPECIAL SENSES

    Signs and symptoms of ocular irritation including conjunctivitis, blepharitis, keratitis, ocular pain, discharge (e.g., crusting), foreign body sensation, itching and tearing, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and diplopia; pseudopemphigoid; choroidal detachment following filtration surgery (see PRECAUTIONS, General); and tinnitus.

    UROGENITAL

    Retroperitoneal fibrosis, decreased libido, impotence, and Peyronie's disease.

    The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; Body as a Whole: Extremity pain, decreased exercise tolerance, weight loss; Cardiovascular: Worsening of arterial insufficiency, vasodilatation; Digestive: Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; Hematologic: Nonthrombocytopenic purpura; thrombocytopenic purpura, agranulocytosis; Endocrine: Hyperglycemia, hypoglycemia; Skin: Pruritus, skin irritation, increased pigmentation, sweating; Musculoskeletal: Arthralgia; Nervous System/Psychiatric: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics; Respiratory: Rales, bronchial obstruction; Urogenital: Urination difficulties.

    Close
  • OVERDOSAGE

    There have been reports of inadvertent overdosage with TIMOPTIC Ophthalmic Solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (see also ADVERSE REACTIONS).

    Overdosage has been reported with Tablets BLOCADREN2 (timolol maleate tablets). A 30-year-old female ingested 650 mg of BLOCADREN (maximum recommended oral daily dose is 60 mg) and experienced second and third degree heart block. She recovered without treatment but approximately two months later developed irregular heartbeat, hypertension, dizziness, tinnitus, faintness, increased pulse rate, and borderline first degree heart block.

    An in vitro hemodialysis study, using 14C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with renal failure showed that timolol did not dialyze readily.


    2
    Registered trademark of MERCK & CO., Inc.
    Close
  • DOSAGE AND ADMINISTRATION

    TIMOPTIC Ophthalmic Solution is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of 0.25 percent TIMOPTIC in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5 percent solution in the affected eye(s) twice a day.

    Since in some patients the pressure-lowering response to TIMOPTIC may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with TIMOPTIC.

    If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

    Dosages above one drop of 0.5 percent TIMOPTIC twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. (See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents.)

    Close
  • HOW SUPPLIED

    Sterile Ophthalmic Solution TIMOPTIC is a clear, colorless to light yellow solution.

    No. 812 — TIMOPTIC Ophthalmic Solution, 0.25% timolol equivalent, is supplied in an OCUMETER®3 PLUS container, a white, translucent, HDPE plastic ophthalmic dispenser with a controlled drop tip and a white polystyrene cap as follows:

    NDC 25010-812-56, 5 mL in a 7.5 mL capacity bottle

    No. 813 — TIMOPTIC Ophthalmic Solution, 0.5% timolol equivalent, is supplied in an OCUMETER® PLUS container, a white translucent, HDPE plastic ophthalmic dispenser with a controlled drop tip and a white polystyrene cap as follows:

    NDC 25010-813-56, 5 mL in a 7.5 mL capacity bottle
    NDC 25010-813-16, 10 mL in an 18 mL capacity bottle.


    3
    Registered trademark of ATON PHARMA, INC.

    Storage

    Store at room temperature, 15-30°C (59-86°F). Protect from freezing. Protect from light.

    Close
  • SPL UNCLASSIFIED SECTION

    Manufactured by: Laboratories Merck Sharp & Dohme-Chibret
    63963 Clermont-Ferrand Cedex 9, France

    Manufactured for: Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807

    Rev. 05/13

    70009232

    Close
  • INSTRUCTIONS FOR USE

    Please follow these instructions carefully when using TIMOPTIC4 . Use TIMOPTIC as prescribed by your doctor.

    1. If you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after TIMOPTIC.
    2. Wash hands before each use.
    3. Before using the medication for the first time, be sure the Safety Strip on the front of the bottle is unbroken. A gap between the bottle and the cap is normal for an unopened bottle.

      Figure

    4. Tear off the Safety Strip to break the seal.

      Figure

    5. To open the bottle, unscrew the cap by turning as indicated by the arrows on the top of the cap. Do not pull the cap directly up and away from the bottle. Pulling the cap directly up will prevent your dispenser from operating properly.

      Figure

    6. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.

      Figure

    7. Invert the bottle, and press lightly with the thumb or index finger over the "Finger Push Area" (as shown) until a single drop is dispensed into the eye as directed by your doctor.

      Figure

    DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP.

    OPHTHALMIC MEDICATIONS, IF HANDLED IMPROPERLY, CAN BECOME CONTAMINATED BY COMMON BACTERIA KNOWN TO CAUSE EYE INFECTIONS. SERIOUS DAMAGE TO THE EYE AND SUBSEQUENT LOSS OF VISION MAY RESULT FROM USING CONTAMINATED OPHTHALMIC MEDICATIONS. IF YOU THINK YOUR MEDICATION MAY BE CONTAMINATED, OR IF YOU DEVELOP AN EYE INFECTION, CONTACT YOUR DOCTOR IMMEDIATELY CONCERNING CONTINUED USE OF THIS BOTTLE.

    8.
    If drop dispensing is difficult after opening for the first time, replace the cap on the bottle and tighten (DO NOT OVERTIGHTEN) and then remove by turning the cap in the opposite direction as indicated by the arrows on the top of the cap.
    9.
    Repeat steps 6 & 7 with the other eye if instructed to do so by your doctor.
    10.
    Replace the cap by turning until it is firmly touching the bottle. The arrow on the left side of the cap must be aligned with the arrow on the left side of the bottle label for proper closure. Do not overtighten or you may damage the bottle and cap.
    11.
    The dispenser tip is designed to provide a single drop; therefore, do NOT enlarge the hole of the dispenser tip.
    12.
    After you have used all doses, there will be some TIMOPTIC left in the bottle. You should not be concerned since an extra amount of TIMOPTIC has been added and you will get the full amount of TIMOPTIC that your doctor prescribed. Do not attempt to remove excess medicine from the bottle.

    WARNING: Keep out of reach of children.

    If you have any questions about the use of TIMOPTIC, please consult your doctor.

    Manufactured by: Laboratories Merck Sharp & Dohme-Chibret
    63963 Clermont-Ferrand Cedex 9, France

    Manufactured for: Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807

    Rev. 05/13

    70009232


    4
    Registered trademark of ATON PHARMA, INC.
    COPYRIGHT © 2013 ATON PHARMA, INC.
    All rights reserved
    Close
  • PRINCIPAL DISPLAY PANEL - 0.25% Carton

    Rx only

    NDC 25010-812-56

    5 mL

    TIMOPTIC®
    (TIMOLOL MALEATE)

    0.25%

    Timolol Equivalent
    (Timolol Maleate 3.4 mg/mL
    equivalent to 2.5 mg/mL timolol)

    Sterile Ophthalmic
    Solution

    Ocumeter® Plus
    Ophthalmic Dispenser

    VALEANT®Ophthalmics

    PRINCIPAL DISPLAY PANEL - 0.25% Carton
    Close
  • PRINCIPAL DISPLAY PANEL - 0.5% Carton

    Rx only

    NDC 25010-813-56

    5 mL

    TIMOPTIC®
    (TIMOLOL MALEATE)

    0.5%

    Timolol Equivalent
    (Timolol Maleate 6.8 mg/mL
    equivalent to 5 mg/mL timolol)

    Sterile Ophthalmic
    Solution

    Ocumeter® Plus
    Ophthalmic Dispenser

    VALEANT®
    Ophthalmics

    PRINCIPAL DISPLAY PANEL - 0.5% Carton
    Close
  • INGREDIENTS AND APPEARANCE
    TIMOPTIC 
    timolol maleate solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:25010-812
    Route of Administration OPHTHALMIC DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Timolol Maleate (Timolol Anhydrous) Timolol Anhydrous 2.5 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    Sodium Phosphate, Monobasic  
    Sodium Phosphate, Dibasic  
    Sodium Hydroxide  
    Water  
    Benzalkonium Chloride  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:25010-812-56 1 in 1 CARTON
    1 5 mL in 1 BOTTLE, DISPENSING
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA018086 08/17/1978
    TIMOPTIC 
    timolol maleate solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:25010-813
    Route of Administration OPHTHALMIC DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Timolol Maleate (Timolol Anhydrous) Timolol Anhydrous 5 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    Sodium Phosphate, Monobasic  
    Sodium Phosphate, Dibasic  
    Sodium Hydroxide  
    Water  
    Benzalkonium Chloride  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:25010-813-56 1 in 1 CARTON
    1 5 mL in 1 BOTTLE, DISPENSING
    2 NDC:25010-813-16 1 in 1 CARTON
    2 10 mL in 1 BOTTLE, DISPENSING
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA018086 08/17/1978
    Labeler - Aton Pharma, Inc. (795419675)
    Establishment
    Name Address ID/FEI Business Operations
    Laboratoires Merck Sharp & Dohme-Chibret 493743686 MANUFACTURE(25010-812, 25010-813)
    Close